John de Koning
John de Koning, Ph.D. is Partner at EQT Life Sciences, formerly LSP, one of Europe’s largest and most experienced healthcare investors, targeting innovative life sciences and health care companies. EQT Life Sciences raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. John joined EQT in 2006, was the driving force behind a large number of investments and served on the Board of Directors of many portfolio companies, such as argenx (NASDAQ: ARGX), Merus (NASDAQ: MRUS), Prosensa (acquired by BioMarin), BMEYE (acquired by Edwards Lifesciences), ONWARD Medical (Euronext: ONWD), eTheRNA, Aelin Therapeutics, XyloCor Therapeutics, Xilis, and VarmX.
John has a Master’s degree in Molecular Biology from the University of Utrecht and a Ph.D. in Oncology from the Erasmus University Rotterdam, both in the Netherlands. After obtaining his Ph.D., he received a prestigious fellowship from the Dutch Cancer Society to work at the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco. His results were published in numerous leading scientific journals, including Nature Genetics.